Midas Management Corp grew its position in Amgen, Inc. (NASDAQ:AMGN) by 7.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,450 shares of the medical research company’s stock after buying an additional 950 shares during the quarter. Midas Management Corp’s holdings in Amgen were worth $2,513,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. FMR LLC increased its position in shares of Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after buying an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Amgen by 0.9% in the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock valued at $8,981,266,000 after buying an additional 489,720 shares in the last quarter. BlackRock Inc. increased its position in shares of Amgen by 1.9% in the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after buying an additional 909,689 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Amgen by 1.7% in the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock valued at $1,522,551,000 after buying an additional 140,117 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Amgen by 12.9% in the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after buying an additional 806,119 shares in the last quarter. Institutional investors and hedge funds own 78.03% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $185.79 on Wednesday. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $201.23. The stock has a market capitalization of $135,825.97, a PE ratio of 72.29, a price-to-earnings-growth ratio of 2.25 and a beta of 1.42.
Amgen announced that its Board of Directors has initiated a share repurchase program on Thursday, February 1st that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.84%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the sale, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders sold 4,575 shares of company stock worth $818,361. 0.19% of the stock is owned by corporate insiders.
A number of analysts recently commented on AMGN shares. Vetr lowered Amgen from a “buy” rating to a “hold” rating and set a $184.25 price objective on the stock. in a research note on Wednesday, January 3rd. Royal Bank of Canada reaffirmed a “hold” rating and set a $189.00 price objective on shares of Amgen in a research note on Wednesday, January 24th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Cann reaffirmed a “buy” rating and set a $205.00 price objective on shares of Amgen in a research note on Thursday, November 30th. Finally, Cowen reaffirmed a “buy” rating and set a $204.00 price objective on shares of Amgen in a research note on Friday, February 2nd. Sixteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Amgen currently has a consensus rating of “Hold” and a consensus target price of $191.72.
COPYRIGHT VIOLATION WARNING: “Amgen, Inc. (AMGN) Shares Bought by Midas Management Corp” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3227525/amgen-inc-amgn-shares-bought-by-midas-management-corp.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.